MUIR GLENN P — SEC insider filings
SEC reporting owner CIK 1181190. 34 insider filings on record with FilingPulse; latest filed 2026-11-20.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2020-08-07 to 2026-11-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 5 filings — 150,171 shares, $760,128 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 51.
- Largest priced transaction: purchase of 50,000 shares @ $13.50 ($675,000) in G1 Therapeutics, Inc., filed 2020-11-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| G1 Therapeutics, Inc. (GTHX) | Director | 6 | 1 leg · 50,000 sh · $675,000 | — | 14 |
| Neuronetics, Inc. (STIM) | Director | 15 | 5 legs · 100,171 sh · $85,128 | — | 11 |
| REPLIGEN CORP (RGEN) | Director | 10 | — | — | 20 |
| Cytek Biosciences, Inc. (CTKB) | Director | 3 | — | — | 6 |
Insider filings — MUIR GLENN P
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-20 | 4 | Cytek Biosciences, Inc. (CTKB) | Option exercise (M): 4,629 · Option exercise (M): 4,629 (derivative) @ $0 | EDGAR |
| 2026-11-19 | 4/A | Neuronetics, Inc. (STIM) | Grant/award (A): 175,000 @ $1.31 | EDGAR |
| 2026-11-18 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 175,000 @ $1.31 | EDGAR |
| 2026-08-20 | 4 | Cytek Biosciences, Inc. (CTKB) | Option exercise (M): 3,086 · Option exercise (M): 3,086 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Cytek Biosciences, Inc. (CTKB) | Grant/award (A): 55,555 (derivative) @ $0 · Grant/award (A): 29,835 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2026-05-18 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 995 @ $0 · Grant/award (A): 2,239 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | REPLIGEN CORP (RGEN) | Option exercise (M): 2,434 @ $38.76 · Option exercise (M): 2,434 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | REPLIGEN CORP (RGEN) | Option exercise (M): 3,366 @ $26.12 · Option exercise (M): 3,366 (derivative) @ $0 | EDGAR |
| 2025-10-22 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 7,554 @ $0 | EDGAR |
| 2025-05-27 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 30,000 | EDGAR |
| 2025-05-19 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 973 @ $0 · Grant/award (A): 1,800 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Neuronetics, Inc. (STIM) | Other (J): 44,444 @ $2.25 | EDGAR |
| 2024-11-20 | 4 | REPLIGEN CORP (RGEN) | Option exercise (M): 19,000 @ $36.29 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | G1 Therapeutics, Inc. (GTHX) | Disposition to issuer (D): 20,000 · Code (U): 185,358 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) | EDGAR |
| 2024-09-06 | 4 | Neuronetics, Inc. (STIM) | Purchase (P): 25,000 @ $0.80 | EDGAR |
| 2024-08-30 | 4 | Neuronetics, Inc. (STIM) | Purchase (P): 12,776 @ $0.85 · Purchase (P): 12,224 @ $0.85 | EDGAR |
| 2024-08-21 | 4 | Neuronetics, Inc. (STIM) | Purchase (P): 25,000 @ $1 | EDGAR |
| 2024-08-16 | 4 | Neuronetics, Inc. (STIM) | Purchase (P): 25,171 @ $0.75 | EDGAR |
| 2024-08-01 | 4 | REPLIGEN CORP (RGEN) | Option exercise (M): 5,000 @ $36.29 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | G1 Therapeutics, Inc. (GTHX) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 25,000 | EDGAR |
| 2024-05-20 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 701 @ $0 · Grant/award (A): 1,376 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | G1 Therapeutics, Inc. (GTHX) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-05-30 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 36,364 | EDGAR |
| 2023-05-22 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 686 @ $0 · Grant/award (A): 1,487 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | G1 Therapeutics, Inc. (GTHX) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 534 @ $0 · Grant/award (A): 1,298 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 38,910 | EDGAR |
| 2021-06-21 | 4 | G1 Therapeutics, Inc. (GTHX) | Grant/award (A): 4,389 @ $0 · Grant/award (A): 19,620 (derivative) @ $0 | EDGAR |
| 2021-06-01 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 7,137 | EDGAR |
| 2021-05-17 | 4 | REPLIGEN CORP (RGEN) | Grant/award (A): 457 @ $0 · Grant/award (A): 1,151 (derivative) @ $0 | EDGAR |
| 2020-11-19 | 4 | G1 Therapeutics, Inc. (GTHX) | Purchase (P): 50,000 @ $13.50 | EDGAR |
| 2020-08-07 | 4 | Neuronetics, Inc. (STIM) | Grant/award (A): 18,513 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1181190 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs